Toward an integrated pipeline for protein biomarker development

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1854, Issue 6, 2015, Pages 677-686

  Drabovich, Andrei P ^a,b   Martínez Morillo, Eduardo ^a   Diamandis, Eleftherios P ^a,b,c,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Biomarker discovery; Biomarker validation; Biomarker verification; Mass spectrometry; Protein biomarker; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

HUMAN; MASS SPECTROMETRY; METABOLISM; PROCEDURES; PROTEOMICS;

BIOLOGICAL MARKERS; BIOMARKERS; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84939941663     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.09.006     Document Type: Review

References (132)

1. A.K. Fuzery, J. Levin, and M.M. Chan Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges Clin. Proteomics 10 2013 13
2. A.S. Ptolemy, and N. Rifai What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema Scand. J. Clin. Lab. Invest. Suppl. 242 2010 6 14
3. N.L. Anderson, and N.G. Anderson The human plasma proteome: history, character, and diagnostic prospects Mol. Cell. Proteomics 1 2002 845 867
4. E.P. Diamandis Cancer biomarkers: can we turn recent failures into success? J. Natl. Cancer Inst. 102 2010 1462 1467
5. E. Anastasi, G.G. Marchei, and V. Viggiani HE4: a new potential early biomarker for the recurrence of ovarian cancer Tumour Biol. 31 2010 113 119
6. R.G. Moore, M.C. Miller, and P. Disilvestro Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass Obstet. Gynecol. 118 2011 280 288
7. P. Legrain, R. Aebersold, and A. Archakov The human proteome project: current state and future direction Mol. Cell. Proteomics 10 2011 (M111 009993)
8. D.S. Wishart, T. Jewison, and A.C. Guo HMDB 3.0 - the human metabolome database in 2013 Nucleic Acids Res. 41 2013 D801 D807
9. O.N. Jensen Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry Curr. Opin. Chem. Biol. 8 2004 33 41
10. U. Landegren, J. Vanelid, and M. Hammond Opportunities for sensitive plasma proteome analysis Anal. Chem. 84 2012 1824 1830
11. L. Hartwell, D. Mankoff, and A. Paulovich Cancer biomarkers: a systems approach Nat. Biotechnol. 24 2006 905 908
12. G.M. McKhann, D.S. Knopman, and H. Chertkow The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 263 269
13. C.R. Jack Jr., M.S. Albert, and D.S. Knopman Introduction to the recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 257 262
14. M.S. Albert, S.T. DeKosky, and D. Dickson The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 270 279
15. R.A. Sperling, P.S. Aisen, and L.A. Beckett Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 280 292
16. B. Krastins, A. Prakash, and D.A. Sarracino Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum Clin. Biochem. 46 2013 399 410
17. S.S. Hori, and S.S. Gambhir Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations Sci. Transl. Med. 3 2011 109ra116
18. D.W. Cramer, R.C. Bast Jr., and C.D. Berg Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prev. Res. (Phila.) 4 2011 365 374
19. K. Ono, T. Tanaka, and T. Tsunoda Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res. 60 2000 5007 5011
20. E.O. Weinberg, M. Shimpo, and S. Hurwitz Identification of serum soluble ST2 receptor as a novel heart failure biomarker Circulation 107 2003 721 726
21. L.B. Schwartz Tryptase: a clinical indicator of mast cell-dependent events Allergy Proc. 15 1994 119 123
22. S. Makawita, C. Smith, and I. Batruch Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers Mol. Cell. Proteomics 10 2011 (M111 008599)
23. P. Picotti, and R. Aebersold Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions Nat. Methods 9 2012 555 566
24. E. Kuhn, J.R. Whiteaker, and D.R. Mani Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma Mol. Cell. Proteomics 11 2012 (M111 013854)
25. S. Peterman, E.E. Niederkofler, and D.A. Phillips An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM) Proteomics 14 2014 1445 1456
26. J.D. Reid, D.T. Holmes, and D.R. Mason Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension J. Am. Soc. Mass Spectrom. 21 2010 1680 1686
27. F. Edfors, T. Boström, and B. Forsström Immunoproteomics using polyclonal antibodies and stable isotope-labeled affinity-purified recombinant proteins Mol. Cell. Proteomics 13 2014 1611 1624
28. D.F. Ransohoff Rules of evidence for cancer molecular-marker discovery and validation Nat. Rev. Cancer 4 2004 309 314
29. T.R. Fleming, and J.H. Powers Biomarkers and surrogate endpoints in clinical trials Stat. Med. 31 2012 2973 2984
30. N.L. Anderson The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum Clin. Chem. 56 2010 177 185
31. J. Li, K.B. Kelm, and Z. Tezak Regulatory perspective on translating proteomic biomarkers to clinical diagnostics J. Proteomics 74 2011 2682 2690
32. A. Konvalinka, J.W. Scholey, and E.P. Diamandis Searching for new biomarkers of renal diseases through proteomics Clin. Chem. 58 2012 353 365
33. A.P. Drabovich, P. Saraon, and K. Jarvi Seminal plasma as a diagnostic fluid for male reproductive system disorders Nat. Rev. Urol. 11 2014 278 288
34. A.P. Drabovich, and E.P. Diamandis Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins J. Proteome Res. 9 2010 1236 1245
35. A.P. Drabovich, M.P. Pavlou, and I. Batruch H.J., I. T.D., V. Proteomic and Metabolomic Approaches to Biomarker Discovery 2013 Elsevier Amsterdam 472
36. J.R. Wisniewski, P. Ostasiewicz, and K. Dus Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma Mol. Syst. Biol. 8 2012 611
37. R. Casadonte, and R.M. Caprioli Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry Nat. Protoc. 6 2011 1695 1709
38. C. Pan, C. Kumar, and S. Bohl Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions Mol. Cell. Proteomics 8 2009 443 450
39. K.K. Frese, and D.A. Tuveson Maximizing mouse cancer models Nat. Rev. Cancer 7 2007 645 658
40. J.C. Tran, L. Zamdborg, and D.R. Ahlf Mapping intact protein isoforms in discovery mode using top-down proteomics Nature 480 2011 254 258
41. A. Moghaddas Gholami, H. Hahne, and Z. Wu Global proteome analysis of the NCI-60 cell line panel Cell Rep. 4 2013 609 620
42. T. Geiger, A. Wehner, and C. Schaab Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins Mol. Cell. Proteomics 11 2012 (M111 014050)
43. A.I. Nesvizhskii, O. Vitek, and R. Aebersold Analysis and validation of proteomic data generated by tandem mass spectrometry Nat. Methods 4 2007 787 797
44. D.N. Perkins, D.J. Pappin, and D.M. Creasy Probability-based protein identification by searching sequence databases using mass spectrometry data Electrophoresis 20 1999 3551 3567
45. D. Fenyo, and R.C. Beavis A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes Anal. Chem. 75 2003 768 774
46. J.K. Eng, A.L. McCormack, and J.R. Yates Iii An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database J. Am. Soc. Mass Spectrom. 5 1994 976 989
47. R.J. Chalkley, P.R. Baker, and L. Huang Comprehensive analysis of a multidimensional liquid chromatography mass spectrometry dataset acquired on a quadrupole selecting, quadrupole collision cell, time-of-flight mass spectrometer: II. New developments in Protein Prospector allow for reliable and comprehensive automatic analysis of large datasets Mol. Cell. Proteomics 4 2005 1194 1204
48. J. Cox, N. Neuhauser, and A. Michalski Andromeda: a peptide search engine integrated into the MaxQuant environment J. Proteome Res. 10 2011 1794 1805
49. N.L. Anderson, M. Polanski, and R. Pieper The human plasma proteome: a nonredundant list developed by combination of four separate sources Mol. Cell. Proteomics 3 2004 311 326
50. J. Adachi, C. Kumar, and Y. Zhang The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins Genome Biol. 7 2006 R80
51. C. Kuk, V. Kulasingam, and C.G. Gunawardana Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers Mol. Cell. Proteomics 8 2009 661 669
52. C.K. Cho, A.P. Drabovich, and I. Batruch Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay J. Proteomics 74 2011 2052 2059
53. I. Batruch, C.R. Smith, and B.J. Mullen Analysis of seminal plasma from patients with non-obstructive azoospermia and identification of candidate biomarkers of male infertility J. Proteome Res. 11 2012 1503 1511
54. B. Pilch, and M. Mann Large-scale and high-confidence proteomic analysis of human seminal plasma Genome Biol. 7 2006 R40
55. P. Saraon, N. Musrap, and D. Cretu Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer J. Biol. Chem. 287 2012 34019 34031
56. A.P. Drabovich, A. Dimitromanolakis, and P. Saraon Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma Sci. Transl. Med. 5 2013 212ra160
57. A.P. Drabovich, K. Jarvi, and E.P. Diamandis Verification of male infertility biomarkers in seminal plasma by multiplex selected reaction monitoring assay Mol. Cell. Proteomics 10 2011 (M110 004127)
58. C.K. Cho, S.J. Shan, and E.J. Winsor Proteomics analysis of human amniotic fluid Mol. Cell. Proteomics 6 2007 1406 1415
59. C.K. Cho, A.P. Drabovich, and G.S. Karagiannis Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome Clin. Proteomics 10 2013 2
60. E. Martinez-Morillo, C.K. Cho, and A.P. Drabovich Development of a multiplex selected reaction monitoring assay for quantification of biochemical markers of Down syndrome in amniotic fluid samples J. Proteome Res. 11 2012 3880 3887
61. H. Kosanam, S. Makawita, and B. Judd Mining the malignant ascites proteome for pancreatic cancer biomarkers Proteomics 11 2011 4551 4558
62. H. Kosanam, I. Prassas, and C.C. Chrystoja Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues Mol. Cell. Proteomics 12 2013 2820 2832
63. Y. Ishihama, Y. Oda, and T. Tabata Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein Mol. Cell. Proteomics 4 2005 1265 1272
64. J. Rappsilber, U. Ryder, and A.I. Lamond Large-scale proteomic analysis of the human spliceosome Genome Res. 12 2002 1231 1245
65. P. Lu, C. Vogel, and R. Wang Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation Nat. Biotechnol. 25 2007 117 124
66. B. Zybailov, A.L. Mosley, and M.E. Sardiu Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae J. Proteome Res. 5 2006 2339 2347
67. N.M. Griffin, J. Yu, and F. Long Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis Nat. Biotechnol. 28 2010 83 89
68. J. Cox, and M. Mann MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 26 2008 1367 1372
69. B. Schwanhausser, D. Busse, and N. Li Global quantification of mammalian gene expression control Nature 473 2011 337 342
70. L.C. Gillet, P. Navarro, and S. Tate Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis Mol. Cell. Proteomics 11 2012 (O111 016717)
71. J.D. Egertson, A. Kuehn, and G.E. Merrihew Multiplexed MS/MS for improved data-independent acquisition Nat. Methods 10 2013 744 746
72. U. Distler, J. Kuharev, and P. Navarro Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics Nat. Methods 11 2014 167 170
73. S. Nahnsen, C. Bielow, and K. Reinert Tools for label-free peptide quantification Mol. Cell. Proteomics 12 2013 549 556
74. C. Ding, J. Jiang, and J. Wei A fast workflow for identification and quantification of proteomes Mol. Cell. Proteomics 12 2013 2370 2380
75. M. Sandin, A. Ali, and K. Hansson An adaptive alignment algorithm for quality-controlled label-free LC-MS Mol. Cell. Proteomics 12 2013 1407 1420
76. D.A. Megger, T. Bracht, and H.E. Meyer Label-free quantification in clinical proteomics Biochim. Biophys. Acta 1834 2013 1581 1590
77. S.E. Ong, B. Blagoev, and I. Kratchmarova Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics Mol. Cell. Proteomics 1 2002 376 386
78. K.H. Yu, C.G. Barry, and D. Austin Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery J. Proteome Res. 8 2009 1565 1576
79. T. Geiger, J. Cox, and P. Ostasiewicz Super-SILAC mix for quantitative proteomics of human tumor tissue Nat. Methods 7 2010 383 385
80. M. Kruger, M. Moser, and S. Ussar SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function Cell 134 2008 353 364
81. P.L. Ross, Y.N. Huang, and J.N. Marchese Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents Mol. Cell. Proteomics 3 2004 1154 1169
82. C. Evans, J. Noirel, and S.Y. Ow An insight into iTRAQ: where do we stand now? Anal. Bioanal. Chem. 404 2012 1011 1027
83. S.P. Gygi, B. Rist, and S.A. Gerber Quantitative analysis of complex protein mixtures using isotope-coded affinity tags Nat. Biotechnol. 17 1999 994 999
84. A. Thompson, J. Schafer, and K. Kuhn Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS Anal. Chem. 75 2003 1895 1904
85. V. Brun, C. Masselon, and J. Garin Isotope dilution strategies for absolute quantitative proteomics J. Proteomics 72 2009 740 749
86. V. Brun, A. Dupuis, and A. Adrait Isotope-labeled protein standards: toward absolute quantitative proteomics Mol. Cell. Proteomics 6 2007 2139 2149
87. R.J. Beynon, M.K. Doherty, and J.M. Pratt Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides Nat. Methods 2 2005 587 589
88. J. Rivers, D.M. Simpson, and D.H. Robertson Absolute multiplexed quantitative analysis of protein expression during muscle development using QconCAT Mol. Cell. Proteomics 6 2007 1416 1427
89. S.A. Gerber, J. Rush, and O. Stemman Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS Proc. Natl. Acad. Sci. U. S. A. 100 2003 6940 6945
90. A.P. Drabovich, M.P. Pavlou, and A. Dimitromanolakis Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay Mol. Cell. Proteomics 11 2012 422 434
91. M.W. Burgess, H. Keshishian, and D.R. Mani Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry Mol. Cell. Proteomics 13 2014 1137 1149
92. J.R. Whiteaker, C. Lin, and J. Kennedy A targeted proteomics-based pipeline for verification of biomarkers in plasma Nat. Biotechnol. 29 2011 625 634
93. R. Simon, M.D. Radmacher, and K. Dobbin Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification J. Natl. Cancer Inst. 95 2003 14 18
94. M. Jenkins, A. Flynn, and T. Smart A statistician's perspective on biomarkers in drug development Pharm. Stat. 10 2011 494 507
95. M.J. Pencina, R.B. D'Agostino, and R.S. Vasan Statistical methods for assessment of added usefulness of new biomarkers Clin. Chem. Lab. Med. 48 2010 1703 1711
96. P. Peduzzi, J. Concato, and E. Kemper A simulation study of the number of events per variable in logistic regression analysis J. Clin. Epidemiol. 49 1996 1373 1379
97. M.S. Pepe, R. Etzioni, and Z. Feng Phases of biomarker development for early detection of cancer J. Natl. Cancer Inst. 93 2001 1054 1061
98. M. Buyse, D.J. Sargent, and A. Grothey Biomarkers and surrogate end points - the challenge of statistical validation Nat. Rev. Clin. Oncol. 7 2010 309 317
99. F. Andre, L.M. McShane, and S. Michiels Biomarker studies: a call for a comprehensive biomarker study registry Nat. Rev. Clin. Oncol. 8 2011 171 176
100. S. Srivastava The early detection research network: 10-year outlook Clin. Chem. 59 2013 60 67
101. G.L. Andriole, E.D. Crawford, and R.L. Grubb III Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J. Natl. Cancer Inst. 104 2012 125 132
102. F.H. Schroder, J. Hugosson, and S. Carlsson Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur. Urol. 62 2012 745 752
103. A. Prakash, T. Rezai, and B. Krastins Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays J. Proteome Res. 9 2010 6678 6688
104. A. Prakash, T. Rezai, and B. Krastins Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies J. Proteome Res. 11 2012 3986 3995
105. T.A. Addona, S.E. Abbatiello, and B. Schilling Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma Nat. Biotechnol. 27 2009 633 641
106. S.A. Carr, S.E. Abbatiello, and B.L. Ackermann Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach Mol. Cell. Proteomics 13 2014 907 917
107. M.F. Lopez, T. Rezai, and D.A. Sarracino Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants Clin. Chem. 56 2010 281 290
108. U. Kuzmanov, N. Jiang, and C.R. Smith Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system Mol. Cell. Proteomics 8 2009 791 798
109. S.L. Neuhausen, S. Brummel, and Y.C. Ding Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers Cancer Epidemiol. Biomarkers Prev. 20 2011 1690 1702
110. CLSI CLSI Document EP06-A 2003 Clinical and Laboratory Standards Institute Wayne, PA
111. CLSI CLSI Document EP05-A2 2004 Clinical and Laboratory Standards Institute Wayne, PA
112. CLSI CLSI Document EP17-A2 2012 Clinical and Laboratory Standards Institute Wayne, PA
113. A. Vegvari, K. Sjodin, and M. Rezeli Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring Mol. Cell. Proteomics 12 2013 2761 2773
114. J.C. Venter, M.D. Adams, and E.W. Myers The sequence of the human genome Science 291 2001 1304 1351
115. K.A. Frazer, D.G. Ballinger, and D.R. Cox A second generation human haplotype map of over 3.1 million SNPs Nature 449 2007 851 861
116. I. Dunham, A. Kundaje, and S.F. Aldred An integrated encyclopedia of DNA elements in the human genome Nature 489 2012 57 74
117. G.R. Abecasis, A. Auton, and L.D. Brooks An integrated map of genetic variation from 1,092 human genomes Nature 491 2012 56 65
118. P.D. Stenson, M. Mort, and E.V. Ball The human gene mutation database: 2008 update Genome Med. 1 2009 13
119. T.J. Hudson, W. Anderson, and A. Artez International network of cancer genome projects Nature 464 2010 993 998
120. P.J. Campbell, P.J. Stephens, and E.D. Pleasance Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing Nat. Genet. 40 2008 722 729
121. J.N. Weinstein, E.A. Collisson, and G.B. Mills The Cancer Genome Atlas Pan-Cancer analysis project Nat. Genet. 45 2013 1113 1120
122. T.C.G.A.R. Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
123. T.C.G.A.R. Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
124. B.E. Bernstein, J.A. Stamatoyannopoulos, and J.F. Costello The NIH roadmap epigenomics mapping consortium Nat. Biotechnol. 28 2010 1045 1048
125. T. Barrett, D.B. Troup, and S.E. Wilhite NCBI GEO: archive for functional genomics data sets - 10 years on Nucleic Acids Res. 39 2010 D1005 D1010
126. M. Kapushesky, T. Adamusiak, and T. Burdett Gene Expression Atlas update - a value-added database of microarray and sequencing-based functional genomics experiments Nucleic Acids Res. 40 2012 D1077 D1081
127. D.F. Ransohoff How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design J. Clin. Epidemiol. 60 2007 1205 1219
128. D.L. Baker, P. Morrison, and B. Miller Plasma lysophosphatidic acid concentration and ovarian cancer JAMA 287 2002 3081 3082
129. G. Piaggio, D.R. Elbourne, and S.J. Pocock Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement JAMA 308 2012 2594 2604
130. D.G. Altman, L.M. McShane, and W. Sauerbrei Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration PLoS Med. 9 2012 e1001216
131. D.A. Zarin, T. Tse, and R.J. Williams The ClinicalTrials.gov results database - update and key issues N. Engl. J. Med. 364 2011 852 860
132. R.J. Fijneman, M. de Wit, and M. Pourghiasian Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer Clin. Cancer Res. 18 2012 2613 2624